-
Innovation Ranking
NewInnovation Ranking – ALK-Abello AS
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and...
-
Product Insights
ALK Tyrosine Kinase Receptor – Drugs In Development, 2023
Global Markets Direct’s ALK Tyrosine Kinase Receptor provides in depth analysis on ALK Tyrosine Kinase Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in ALK Tyrosine Kinase...
-
Sector Analysis
ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
ALK Tests Market Report Overview The ALK Tests market size was valued at $27.3 million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells, the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC). ALK Tests Market Outlook 2023-2023 ($ Million) Buy The Full Report for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Idiopathic Hypersomnia (IH) Drug Details: ALKS-2680 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)...
-
Company Insights
Innovation and Patenting activity of ALK-Abello AS Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ALK-Abello AS Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Non-Small Cell Lung Cancer Drug Details: Golidocitinib (DZD-4205)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Cutaneous T-Cell Lymphoma Drug Details: Golidocitinib (DZD-4205) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golidocitinib in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Sezary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golidocitinib in Sezary Syndrome Drug Details: Golidocitinib (DZD-4205) is under development for...